PD-L1/B7-H1 Antibody from R&D Systems, a Bio-Techne Brand

Yes, the PD-L1/B7-H1 antibody has been shown to work in feline studies, as indicated by its reactivity with feline species. Research has demonstrated that feline adipose-derived mesenchymal stem cells express PD-L1, and the antibody can be utilized to investigate its role in T cell modulation in these models (Taechang et al., 2019).

The PD-L1/B7-H1 antibody has been effectively used in various applications, including Western blotting and immunohistochemistry, to detect PD-L1 expression in human cancer cell lines. For instance, it was employed in studies examining the PD-1/PD-L1 axis in breast and prostate cancer cells, demonstrating its utility in assessing PD-L1 levels in response to therapeutic interventions (Black et al., 2016; Burr et al., 2017).

Yes, the PD-L1/B7-H1 antibody has been cited in studies utilizing flow cytometry to analyze PD-L1 expression on cell surfaces. It has been used to confirm PD-L1 knockdown in various cell lines, indicating its effectiveness in flow cytometric applications (Burr et al., 2017).

The PD-L1/B7-H1 antibody is significant in immunotherapy research, particularly in studies exploring the blockade of the PD-1/PD-L1 pathway. For example, it has been shown that inhibiting this pathway can enhance the efficacy of chemotherapeutic agents, suggesting that this antibody could be pivotal in developing combination therapies for cancer treatment (Black et al., 2016; Thampy et al., 2018).